Brief: Nuvation Bio Announces FDA Clearance Of Investigational New Drug Application For NUV-1511
08/01/2024 22:10
Jan 8 (Reuters) - Nuvation Bio Inc NUVB.N :
* NUVATION BIO ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW DRUG
APPLICATION FOR NUV-1511 FOR THE TREATMENT OF ADVANCED SOLID
TUMORS
* NUVATION BIO INC - COMPANY ANTICIPATES INITIATING A PHASE
1/2
CLINICAL STUDY OF NUV-1511 IN 1H 2024
Source text for Eikon: ID:nBw5DT4wwa
Further company coverage: NUVB.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth